3651 results for «211»

Filter By

3651 results

Calcified lesions: when one dedicated device is not enough

22 May 2026 – From EuroPCR 2026

This session highlights the need for multiple dedicated devices in the treatment of calcified coronary lesions. It discusses combined orbital and rotational atherectomy techniques, debulking in complex high-risk patients, and the integration of atherectomy with intravascular lithotripsy systems. Emphasis is placed on physiology and imaging-guided approaches...

Overcoming complications with intracoronary imaging

21 May 2026 – From EuroPCR 2026

Explore challenging cases of intracoronary imaging complications, highlighting recognition, management, and resolution of complex vascular and mechanical issues encountered during coronary interventions.

Innovative strategies in STEMI management

22 May 2026 – From EuroPCR 2026

This session presents innovative strategies in STEMI management, including the treatment of acute saphenous vein graft occlusion, primary PCI via the left internal mammary artery, and a two-step lesion debulking approach. It also covers hybrid drug-coated balloon strategies in complex multivessel disease and the emerging role...

Atypical NSTEMI culprit lesions

22 May 2026 – From EuroPCR 2026

Focusing on atypical NSTEMI culprit lesions, this session examines rare presentations such as calcific emboli, coronary anomalies, and unusual routes to revascularisation. It provides clinical insights into diagnosing and managing uncommon acute coronary syndromes effectively.

Clinical decision making for CTO PCI strategy

22 May 2026 – From EuroPCR 2026

This session explores clinical decision-making in CTO PCI strategy through complex scenarios including multivessel CTO in ischemic cardiomyopathy, high-risk NSTEMI post-vein graft failure, and challenges in elderly patients. It emphasizes strategic planning and individualized approaches to optimize outcomes.

Spontaneous coronary artery dissection management with intracoronary imaging

22 May 2026 – From EuroPCR 2026

Explore the nuanced management of spontaneous coronary artery dissection (SCAD) with a focus on intracoronary imaging. This session examines diagnostic challenges, the limited role of coronary CT angiography, and strategies for managing occlusive SCAD cases, highlighting the evolving understanding of this complex condition.

Diversity in coronary artery disease treatment

22 May 2026 – From EuroPCR 2026

Focusing on the diversity in coronary artery disease treatment, this session highlights challenges ranging from maintaining interventional cardiology services during conflict to the influence of comorbidities such as type 2 diabetes mellitus on prognosis and risk assessment. It also presents clinical outcomes related to stent thrombosis...

Left main PCI-complex procedures

22 May 2026 – From EuroPCR 2026

This session covers complex left main coronary artery PCI procedures that challenge standard algorithms. It includes tackling chronic total occlusions of the left main, managing spontaneous coronary artery dissection in patients on ECMO, handling stent dislodgement, and addressing complex trifurcation lesions, providing comprehensive insights into advanced...

PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial

18 May 2021

Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...

PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial

INFINITY-SWEDEHEART - Percutaneous coronary intervention with a bioadaptor compared to a contemporary drug eluting stent- one year primary outcomes

03 Sep 2024

Daniele Giacoppo provides his take on the main results of the INFINITY-SWEDEHEART trial presented by David Erlinge at the ESC Congress 2024 in London.

Daniele Giacoppo

Author

Daniele Giacoppo
INFINITY-SWEDEHEART

BioCardia reports positive interim results from phase III CardiAMP cell therapy heart failure trial, with compelling data in subgroup with elevated NTproBNP biomarker for heart failure.

04 Mar 2024

Didn’t find what you were looking for?